www.idosr.org
Masika
©IDOSR PUBLICATIONS
ISSN: 2550-794X
International Digital Organization for Scientific Research
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):109-116, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.3.109116
IDOSRJSR10.300000

Tumor Microenvironment Modulation Using Nanotechnology: Reprogramming the Cancer Ecosystem

Masika Anna Mahinda

Department of Pharmacy Kampala International University Uganda
Email: mahindamasika@studwc.kiu.ac.ug

ABSTRACT

The tumor microenvironment (TME) plays a pivotal role in cancer initiation, progression, metastasis, and therapeutic resistance. It comprises a dynamic and complex network of tumor cells, stromal cells, immune cells, extracellular matrix (ECM), cytokines, and blood vessels that collectively support tumor growth. Conventional cancer therapies often fail to address the multifaceted nature of the TME, resulting in limited efficacy and relapse. Nanotechnology offers an innovative platform to precisely modulate the TME by reprogramming its components and restoring antitumor immunity. This review provides a comprehensive analysis of the current advances in nanotechnology-based strategies for TME modulation, including normalization of tumor vasculature, remodeling of the ECM, reprogramming of tumor-associated macrophages (TAMs), targeting cancer-associated fibroblasts (CAFs), alleviating hypoxia, and modulating immunosuppressive pathways. We also discuss the design considerations of nanocarriers, such as size, surface charge, and targeting ligands, which enhance their accumulation and retention in the tumor site. Furthermore, we highlight the integration of nanotechnology with emerging therapies such as immune checkpoint inhibitors, CAR-T cells, and tumor vaccines to achieve synergistic effects. Despite promising preclinical results, challenges remain in translating these approaches to the clinic due to heterogeneity of the TME, nanotoxicity concerns, and regulatory hurdles. Future perspectives call for the development of multifunctional, stimuli-responsive, and personalized nanomedicine to achieve efficient TME reprogramming and improved cancer outcomes.

Keywords: Tumor microenvironment, Nanotechnology, Immune modulation, Cancer therapy, Tumor reprogramming

INTRODUCTION

Cancer remains one of the most formidable health challenges globally, characterized by its multifactorial nature and resistance to conventional therapies[1–4]. While the genetic and epigenetic alterations of cancer cells have historically been at the center of oncological research and treatment strategies, it is now well established that tumor progression and therapeutic resistance are not determined by malignant cells alone[5, 6]. Rather, cancer thrives in a complex and dynamic milieu known as the tumor microenvironment (TME)[7–9]. The TME is composed of a heterogeneous population of stromal and immune cells, blood and lymphatic vessels, extracellular matrix (ECM), and a cocktail of signaling molecules including cytokines, chemokines, and growth factors. These components engage in a sophisticated network of interactions with cancer cells, collectively influencing tumor growth, angiogenesis, metastasis, immune evasion, and response to treatment[10, 11].

Importantly, the TME acts as both a barrier and an enabler. On one hand, it can suppress immune recognition and promote drug resistance, thereby shielding cancer cells from therapeutic interventions[12, 13]. On the other hand, it presents a rich array of novel targets for therapeutic modulation. Traditional cancer treatments, such as chemotherapy and radiotherapy, primarily focus on directly killing rapidly dividing tumor cells[14–16]. However, these approaches often fail to address the supportive TME elements that facilitate tumor survival and relapse. As a result, even after substantial tumor reduction, recurrence is common due to residual malignant cells nurtured by an unaltered microenvironment[15, 17, 18].

Recent advancements in nanotechnology have opened new frontiers in the field of oncology by enabling the design of nanoscale drug delivery systems that can selectively target both tumor cells and their supportive microenvironment[19–21]. Nanoparticles, liposomes, dendrimers, micelles, and inorganic nanocarriers can be engineered to carry therapeutic agents ranging from small molecules and peptides to nucleic acids directly to specific components within the TME[22–24]. These platforms offer several advantages over conventional

therapies, including enhanced permeability and retention (EPR) effect-based accumulation in tumors, controlled and stimuli-responsive drug release, and the ability to bypass physiological barriers.

The use of nanotechnology in modulating the TME is a particularly promising strategy because it allows for multimodal reprogramming of the cancer ecosystem[25–27]. For instance, nanoparticles can be loaded with agents that repolarize tumor-associated macrophages (TAMs) from a pro-tumorigenic (M2-like) phenotype to an anti-tumorigenic (M1-like) state. Similarly, nanoformulations can be designed to normalize the aberrant vasculature in tumors, alleviate hypoxia, modulate the ECM for improved drug penetration, and disrupt immune-suppressive signaling networks[28–30]. This system-level approach not only enhances the efficacy of existing treatments but also reduces the likelihood of resistance and disease relapse.

Moreover, nanotechnology enables the integration of diagnostic and therapeutic functionalities into a single platform commonly referred to as "theranostics." Such systems allow real-time imaging of drug distribution and therapeutic response, facilitating personalized and adaptive treatment strategies[31–33].

This review aims to provide a comprehensive overview of the recent progress in nanotechnology-based modulation of the tumor microenvironment. We begin with an in-depth examination of the components and functional dynamics of the TME, followed by a discussion on how nanotechnology is being employed to target different TME elements. Finally, we explore emerging strategies, clinical translation efforts, and future directions in this rapidly evolving field. By reprogramming the cancer ecosystem toward a more hostile environment for tumors, these innovative nanotechnological approaches hold the potential to transform the therapeutic landscape and improve patient outcomes.

2. The Tumor Microenvironment: An Overview

The tumor microenvironment (TME) is a highly dynamic and interactive network that plays a crucial role in dictating cancer initiation, progression, metastasis, and response to therapy. Rather than being a passive bystander, the TME actively supports tumorigenesis through biochemical and mechanical cues[34, 35]. This intricate ecosystem comprises both cellular and non-cellular components, each contributing uniquely to the malignant phenotype and therapeutic resistance. Among the key cellular components of the TME are:

Tumor-Associated Macrophages (TAMs): These immune cells typically exhibit an M2-like phenotype within tumors, promoting immunosuppression, angiogenesis, and tissue remodeling. TAMs are known to release cytokines such as IL-10 and TGF-β, which dampen cytotoxic T-cell responses and facilitate tumor immune evasion[36, 37].

Cancer-Associated Fibroblasts (CAFs): CAFs are activated stromal cells that secrete growth factors (e.g., VEGF, FGF), ECM components (e.g., collagen, fibronectin), and proteases (e.g., MMPs). These factors enhance ECM remodeling, tumor cell invasion, and angiogenesis while also creating physical barriers to drug penetration[38].

Regulatory T Cells (Tregs): Tregs suppress effector T-cell function and promote immune tolerance within the tumor. High infiltration of Tregs in tumors is associated with poor prognosis and reduced efficacy of immunotherapies[39, 40].

Myeloid-Derived Suppressor Cells (MDSCs): These immature immune cells inhibit both innate and adaptive immune responses by producing nitric oxide, ROS, and arginase, thereby fostering a tolerogenic environment[41, 42].

Endothelial Cells and Pericytes: These cells form the tumor vasculature, which is often abnormal, leaky, and poorly organized. The resulting hypoxia and poor perfusion contribute to immune suppression and hinder drug delivery[43].

The non-cellular elements of the TME are equally important. For instance:

Extracellular Matrix (ECM): The ECM provides structural support but also acts as a biochemical signaling hub. Its dense and irregular architecture can obstruct therapeutic penetration and serve as a reservoir for growth factors[44].

Hypoxia: Rapid tumor growth often outpaces vascular supply, leading to regions of low oxygen tension. Hypoxia induces the expression of hypoxia-inducible factors (HIFs), which in turn promote angiogenesis, metabolic reprogramming, and resistance to therapy[45].

Acidosis and Oxidative Stress: Tumor cells rely heavily on glycolysis, leading to the accumulation of lactic acid and a drop in extracellular pH. This acidic environment can promote invasion and suppress immune function. Similarly, elevated ROS levels drive DNA damage and genomic instability[46, 47]. Together, these components create a pro-tumorigenic niche that sustains malignant growth, facilitates metastasis, and contributes to therapeutic failure. Therefore, targeting the TME is a compelling strategy that aims to reprogram this supportive niche into one that is hostile to cancer cells. This involves modulating immune cell activity, normalizing the vasculature, degrading or remodeling the ECM, and alleviating hypoxia[48].

Nanotechnology offers a powerful toolkit for such interventions. Engineered nanoparticles can deliver reprogramming agents selectively to the TME, modify the immune milieu, and enhance the penetration of chemotherapeutic drugs. For example, nanoparticles loaded with HIF-1α inhibitors can reduce hypoxia-induced resistance, while those delivering matrix-degrading enzymes can enhance drug diffusion. Additionally, nanocarriers can be functionalized with ligands or antibodies to home in on specific TME cell types like TAMs or CAFs[32, 49]. A comprehensive understanding of the TME's composition and function is essential for

designing effective therapeutic strategies. Modulating the TME, especially through the precision afforded by nanotechnology, represents a paradigm shift from traditional tumor-centric approaches to a more holistic and systemic treatment model.

3. Nanotechnology for Tumor Microenvironment Modulation

3.1 Nanocarrier Design for Targeted TME Modulation

The design of nanocarriers plays a critical role in targeting and modulating the tumor microenvironment (TME). By engineering nanoparticles with precise control over size, shape, surface charge, and surface chemistry, researchers can enhance tumor selectivity and therapeutic efficacy[50, 51]. Typically, nanocarriers sized between 10–100 nm can exploit the enhanced permeability and retention (EPR) effect for passive targeting due to the leaky vasculature and poor lymphatic drainage in tumors.[50, 52] Beyond passive mechanisms, active targeting can be achieved by functionalizing nanoparticles with ligands or antibodies that bind to overexpressed receptors on cancer cells or TME components such as integrins, folate receptors, or CD44[53, 54]. Furthermore, stimuli-responsive nanoparticles have been developed to release their therapeutic payload in response to TME-specific stimuli such as acidic pH, elevated enzyme levels (e.g., matrix metalloproteinases), or redox gradients (e.g., glutathione). These smart nanocarriers ensure drug release only in the tumor milieu, minimizing systemic toxicity. Such precision enhances the therapeutic index and allows for multi-modal intervention, such as delivering gene silencers, chemotherapeutics, or immune modulators. In essence, rational nanocarrier design enables spatiotemporal control of therapeutic interventions within the TME, offering a promising strategy for reprogramming the tumor ecosystem toward a state more conducive to cancer eradication.

3.2 Remodeling the Extracellular Matrix (ECM)

The extracellular matrix (ECM) within the tumor microenvironment acts as a physical and biochemical barrier that limits the penetration of drugs, immune cells, and therapeutic agents. This dense and disorganized matrix, composed of collagen, fibronectin, and hyaluronan, contributes to elevated interstitial pressure and restricted tissue perfusion, ultimately promoting therapeutic resistance and tumor progression[55]. Nanotechnology offers innovative strategies to remodel this hostile ECM. One approach involves encapsulating ECM-degrading enzymes such as collagenase and hyaluronidase within nanoparticles, which protect the enzymes from degradation and enable targeted delivery to the tumor site[56]. By enzymatically degrading ECM components, these nanocarriers facilitate better infiltration of chemotherapeutics and immune cells. Another strategy involves delivering matrix metalloproteinase inhibitors (MMPIs) to suppress excessive ECM degradation, which can otherwise promote metastasis. This dual capability of either degrading or stabilizing the ECM depending on tumor context highlights the versatility of nanoparticles. Additionally, some nanocarriers are engineered to co-deliver ECM-targeting agents alongside traditional chemotherapeutics, resulting in synergistic effects on tumor shrinkage and metastasis prevention[57]. Ultimately, ECM remodeling via nanotechnology represents a key strategy to improve the mechanical properties of the TME, enhance drug delivery, and overcome a critical barrier to effective cancer therapy[57].

3.3 Reprogramming Tumor-Associated Macrophages (TAMs)

Tumor-associated macrophages (TAMs) are a major component of the TME and often adopt an M2-like phenotype that promotes tumor progression, angiogenesis, and immunosuppression. Reprogramming these macrophages into the pro-inflammatory, anti-tumor M1 phenotype has become a promising therapeutic strategy[26, 28, 29]. Nanoparticles serve as highly effective delivery vehicles for this purpose. Liposomes, polymeric nanoparticles, and inorganic nanocarriers such as gold or silica nanoparticles can encapsulate agents like toll-like receptor (TLR) agonists, colony-stimulating factor 1 receptor (CSF-1R) inhibitors, or small interfering RNAs (siRNAs) targeting M2-polarizing transcription factors (e.g., STAT6)[28]. These agents, when delivered specifically to TAMs, can induce phenotypic switching toward M1-like macrophages, restoring their ability to present antigens, secrete pro-inflammatory cytokines (e.g., TNF-α, IL-12), and support cytotoxic T cell responses. Surface modification of nanoparticles with mannose or scavenger receptor ligands enables selective uptake by TAMs, enhancing specificity[58, 59]. In addition to repolarization, nanoparticles can also deplete TAMs or block their recruitment to tumors by delivering chemokine receptor inhibitors. Reprogramming TAMs not only reduces tumor-promoting signals but also rejuvenates anti-tumor immunity, making it a compelling adjunct to immunotherapies. Overall, nanotechnology offers precise and potent tools for reshaping the immunological landscape of the TME through TAM modulation.

3.4 Targeting Cancer-Associated Fibroblasts (CAFs)

Cancer-associated fibroblasts (CAFs) are critical stromal components within the tumor microenvironment, playing essential roles in extracellular matrix remodeling, immune suppression, and therapeutic resistance[60]. Their activation contributes to increased matrix stiffness, desmoplasia, and secretion of immunosuppressive cytokines such as TGF-β and IL-6, all of which create a protective niche for tumor growth. Targeting CAFs using nanotechnology offers a promising strategy to mitigate these pro-tumorigenic effects[61]. Nanoparticles can be functionalized with ligands specific to CAF markers such as fibroblast activation protein-alpha (FAP-α), PDGFR-β, or α-SMA. These targeted systems deliver cytotoxic agents, chemotherapeutics, or gene-silencing tools (e.g., siRNA, antisense oligonucleotides) directly to CAFs, selectively depleting or reprogramming them[61]. Alternatively, nanoparticles can be engineered to deliver inhibitors of CAF-derived signaling

pathways or cytokines, thereby reducing their pro-tumorigenic influence. Importantly, modulating CAF activity leads to decreased ECM stiffness and improved vascular normalization, which in turn enhances immune cell infiltration and drug delivery[61]. However, complete ablation of CAFs can sometimes exacerbate tumor aggressiveness, emphasizing the need for strategies that modulate rather than eliminate their activity. Nanotechnology thus provides the means to selectively and reversibly alter CAF behavior, reshaping the TME to favor tumor regression and improve response to conventional and immunotherapeutic interventions.

3.5 Modulating Tumor Vasculature and Hypoxia

Abnormal tumor vasculature is a hallmark of the TME, characterized by disorganized, leaky, and inefficient blood vessels that contribute to poor perfusion, hypoxia, and impaired drug delivery. These conditions not only limit therapeutic efficacy but also promote tumor aggression and resistance[62]. Nanoparticle-based strategies are increasingly employed to normalize the tumor vasculature and alleviate hypoxia. Nanocarriers can be used to deliver angiogenesis inhibitors such as bevacizumab (anti-VEGF antibody) or small-molecule inhibitors targeting VEGF/VEGFR signaling, thus reducing abnormal neovascularization. Additionally, vascular normalization agents like angiotensin receptor blockers (e.g., losartan) or nitric oxide donors can be encapsulated in nanoparticles to improve perfusion and oxygen delivery[62]. Moreover, oxygen-generating nanoparticles, including catalase-loaded systems or perfluorocarbon-based carriers, are being developed to locally release oxygen in hypoxic tumor regions[63]. These approaches restore tissue oxygenation, thereby enhancing the efficacy of radiotherapy and immunotherapy. Some nanoparticles are designed to be hypoxia-sensitive, releasing their payload only in low-oxygen conditions, which increases specificity and reduces systemic toxicity[63]. Overall, nanotechnology-mediated modulation of tumor vasculature and hypoxia holds significant potential in overcoming physiological barriers within the TME and improving therapeutic outcomes across multiple cancer types.

3.6 Enhancing Immunotherapy via Nanotechnology

Nanotechnology has revolutionized the field of cancer immunotherapy by enabling precise and efficient delivery of immune modulators to the tumor microenvironment[64]. Nanoparticles can be engineered to carry immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, CTLA-4), cytokines (e.g., IL-2, GM-CSF), and tumor-associated antigens to enhance the activation of the immune system against cancer cells[64]. These carriers offer controlled release, protection from degradation, and improved pharmacokinetics of immunotherapeutic agents. Nanovaccines nanoparticles co-loaded with antigens and adjuvants can be used to stimulate dendritic cell maturation and promote robust T cell priming. Furthermore, nanoparticles can selectively target and disrupt immunosuppressive networks in the TME, such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), thereby restoring antitumor immunity[65]. Dual- or multi-functional nanoparticles capable of co-delivering immunotherapeutics with chemotherapeutics or gene silencers provide synergistic benefits. In addition, nanoscale delivery platforms reduce off-target effects and enhance the accumulation of immune modulators at the tumor site via the enhanced permeability and retention (EPR) effect. With ongoing advancements, nanotechnology is expected to further boost the efficacy and precision of immunotherapies, transforming immune-cold tumors into immune-responsive ones and expanding the benefit of cancer immunotherapy to a broader patient population[65].

4. Clinical Translation and Challenges

Although preclinical studies have demonstrated significant promise, the clinical translation of tumor microenvironment (TME)-modulating nanotherapies is fraught with considerable challenges.[66] One major hurdle is tumor heterogeneity, which results in varied expression of molecular targets and inconsistent enhanced permeability and retention (EPR) effects across patients, limiting effective and uniform drug delivery. Furthermore, the long-term biocompatibility, nanotoxicity, and potential immunogenicity of these materials remain unresolved, raising concerns about safety and tolerability[66]. Regulatory frameworks for evaluating nanomedicines are still evolving, often lacking specific guidelines tailored to their unique physicochemical properties. Stringent requirements for pharmacokinetic, biodistribution, and toxicological data slow down clinical advancement. To address these barriers, a multidisciplinary approach that integrates nanotechnology with systems biology, immunology, and precision medicine is critical[66]. Collaborative efforts between academia, industry, and regulatory bodies are essential to standardize evaluation metrics and ensure the safe and effective translation of TME-modulating nanotherapeutics into routine oncology practice.

5. Future Perspectives

Looking ahead, the future of TME-targeted nanomedicine lies in the development of intelligent, multifunctional, and biomimetic nanoplatforms capable of performing multiple tasks within the tumor milieu. These advanced systems may integrate stimuli-responsive behavior, enabling site-specific activation and minimized off-target effects. Additionally, artificial intelligence (AI) and machine learning are expected to play transformative roles by optimizing nanoparticle design, predicting therapeutic outcomes, and enabling patient-specific customization. The convergence of nanotechnology with innovative modalities such as gene editing tools (e.g., CRISPR), oncolytic viruses, and neoantigen-based cancer vaccines may unlock new levels of therapeutic precision and efficacy. A key goal is to transform immunologically "cold" tumors, which are non-responsive to immunotherapy, into "hot" tumors that exhibit robust immune infiltration and responsiveness. By remodeling the TME, future nanotherapies have the potential to synergize with conventional treatments and

immunotherapies, improving patient outcomes and achieving long-term remission in otherwise treatment-resistant cancers.

CONCLUSION

Nanotechnology-driven modulation of the tumor microenvironment (TME) marks a pivotal shift in cancer treatment paradigms from traditional tumor-centric strategies to comprehensive ecosystem-level interventions. By targeting and reprogramming the various cellular and molecular constituents of the TME, nanomedicine holds the potential to overcome longstanding challenges in oncology, including therapeutic resistance, immune suppression, and poor drug penetration. This approach enables a multifaceted attack on cancer, enhancing drug delivery, restoring immune surveillance, and disrupting tumor-stromal interactions. However, for this promise to translate into clinical success, continued innovation in nanomaterial design, combined with rigorous safety assessments and strategic clinical trials, is necessary. Integration with personalized medicine approaches and real-time patient profiling will further improve precision and therapeutic relevance. As research and development progress, nanotechnology-based TME modulation stands to redefine cancer care by enabling more durable, targeted, and effective treatments that go beyond tumor shrinkage to long-term disease control.

REFERENCES

1. Shirzad, M., Shaban, M., Mohammadzadeh, V., Rahdar, A., Fathi-karkan, S., Hoseini, Z.S., Najafi, M., Kharaba, Z., Aboudzadeh, M.A.: Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions. BioNanoSci. 15, 354 (2025). https://doi.org/10.1007/s12668-025-01980-w
2. Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J.E.N., Hamblin, M.R.: PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 12, 177–190 (2018). https://doi.org/10.1016/j.apmt.2018.05.002
3. Abolhassani, H., Eskandari, A., Saremi Poor, A., Zarrabi, A., Khodadadi, B., Karimifard, S., Sahrayi, H., Bourbour, M., Tavakkoli Yaraki, M.: Nanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro models. Coordination Chemistry Reviews. 508, 215754 (2024). https://doi.org/10.1016/j.ccr.2024.215754
4. Tufail, T., Uti, D.E., Aja, P.M., Offor, C.E., Ibiam, U.A., Ukaidi, C.U.A.: Utilizing Indigenous Flora in East Africa for Breast Cancer Treatment: An Overview. Anticancer Agents Med Chem. 25, 99–113 (2025). https://doi.org/10.2174/0118715206338557240909081833
5. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
6. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discover Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
7. Cao, Y., Yi, Y., Han, C., Shi, B.: NF-κB signaling pathway in tumor microenvironment. Front. Immunol. 15, (2024). https://doi.org/10.3389/fimmu.2024.1476030
8. Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., Zhang, Q.: Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 7, 538–558 (2017). https://doi.org/10.7150/thno.16684
9. de Visser, K.E., Joyce, J.A.: The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41, 374–403 (2023). https://doi.org/10.1016/j.ccell.2023.02.016
10. Chen, X., Zheng, Y., Zhang, Q., Chen, Q., Chen, Z., Wu, D.: Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma. Journal of Nanobiotechnology. 22, 264 (2024). https://doi.org/10.1186/s12951-024-02531-3
11. He, Q., Chen, J., Yan, J., Cai, S., Xiong, H., Liu, Y., Peng, D., Mo, M., Liu, Z.: Tumor microenvironment responsive drug delivery systems. Asian J Pharm Sci. 15, 416–448 (2020). https://doi.org/10.1016/j.ajps.2019.08.003
12. Huai, Y., Hossen, M.N., Wilhelm, S., Bhattacharya, R., Mukherjee, P.: Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 30, 2247–2263 (2019). https://doi.org/10.1021/acs.bioconjchem.9b00448
13. Issa, H., Singh, L., Lai, K.-S., Parusheva-Borsitzky, T., Ansari, S.: Dynamics of inflammatory signals within the tumor microenvironment. World J Exp Med. 15, 102285 (2025). https://doi.org/10.5493/wjem.v15.i2.102285
14. Aghajanzadeh, M., Zamani, M., Rajabi Kouchi, F., Eixenberger, J., Shirini, D., Estrada, D., Shirini, F.: Synergic Antitumor Effect of Photodynamic Therapy and Chemotherapy Mediated by Nano Drug Delivery Systems. Pharmaceutics. 14, 322 (2022). https://doi.org/10.3390/pharmaceutics14020322
15. Cao, L., Zhu, Y., Wang, W., Wang, G., Zhang, S., Cheng, H.: Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy. Front. Bioeng. Biotechnol. 9, (2021). https://doi.org/10.3389/fbioe.2021.798882

16. Alum, E.U.: AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov Onc. 16, 313 (2025). https://doi.org/10.1007/s12672-025-02064-7
17. Lee, C.K., Davies, L., Wu, Y.-L., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., Lord, S., Marschner, I., Tu, Y.-K., Gralla, R.J., Gebski, V., Mok, T., Yang, J.C.-H.: Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 109, (2017). https://doi.org/10.1093/jnci/djw279
18. Oner, G., Önder, S., Karatay, H., Ak, N., Tükenmez, M., Müslümanoğlu, M., İğci, A., Dincçağ, A., Özmen, V., Aydiner, A., Yavuz, E., Cabioğlu, N.: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World J Surg Oncol. 19, 264 (2021). https://doi.org/10.1186/s12957-021-02361-9
19. Ammar, M.M., Ali, R., Abd Elaziz, N.A., Habib, H., Abbas, F.M., Yassin, M.T., Maniah, K., Abdelaziz, R.: Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics. Discov Onc. 16, 1172 (2025). https://doi.org/10.1007/s12672-025-02664-3
20. Haleem, A., Javaid, M., Singh, R.P., Rab, S., Suman, R.: Applications of nanotechnology in medical field: a brief review. Global Health Journal. 7, 70–77 (2023). https://doi.org/10.1016/j.glohj.2023.02.008
21. Haleem, A., Javaid, M., Singh, R.P., Rab, S., Suman, R.: Applications of nanotechnology in medical field: a brief review. Global Health Journal. 7, 70–77 (2023). https://doi.org/10.1016/j.glohj.2023.02.008
22. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv Pharm Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
23. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef University Journal of Basic and Applied Sciences. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
24. Bozzer, S., Dal Bo, M., Grimaldi, M.C., Toffoli, G., Macor, P.: Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies. Pharmaceutics. 14, 1965 (2022). https://doi.org/10.3390/pharmaceutics14091965
25. Allemailem, K.S., Alsahli, M.A., Almatroudi, A., Alrumaihi, F., Al Abdulmonem, W., Moawad, A.A., Alwanian, W.M., Almansour, N.M., Rahmani, A.H., Khan, A.A.: Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management. Int J Nanomedicine. 18, 5531–5559 (2023). https://doi.org/10.2147/IJN.S424872
26. Bae, W., Ra, E.A., Lee, M.H.: Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Front Cell Dev Biol. 13, 1559183 (2025). https://doi.org/10.3389/fcell.2025.1559183
27. Cheng, Z., Zheng, L., Almeida, F.A.: Epigenetic reprogramming in metabolic disorders: nutritional factors and beyond. J Nutr Biochem. 54, 1–10 (2018). https://doi.org/10.1016/j.jnutbio.2017.10.004
28. Mao, Y., Xia, Z., Xia, W., Jiang, P.: Metabolic reprogramming, sensing, and cancer therapy. Cell Reports. 43, 115064 (2024). https://doi.org/10.1016/j.celrep.2024.115064
29. Wang, Q., Liu, J., Chen, Z., Zheng, J., Wang, Y., Dong, J.: Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review. Biomedicine & Pharmacotherapy. 170, 116021 (2024). https://doi.org/10.1016/j.biopha.2023.116021
30. Zhang, J., Gao, P., Chang, W.-R., Song, J.-Y., An, F.-Y., Wang, Y.-J., Xiao, Z.-P., Jin, H., Zhang, X.-H., Yan, C.-L.: The role of HIF-1α in hypoxic metabolic reprogramming in osteoarthritis. Pharmacological Research. 213, 107649 (2025). https://doi.org/10.1016/j.phrs.2025.107649
31. Kumarasamy, R.V., Natarajan, P.M., Umapathy, V.R., Roy, J.R., Mironescu, M., Palanisamy, C.P.: Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Front. Nanotechnol. 6, (2024). https://doi.org/10.3389/fnano.2024.1479993
32. Khan, Y., Sadia, H., Ali Shah, S.Z., Khan, M.N., Shah, A.A., Ullah, N., Ullah, M.F., Bibi, H., Bafakeeh, O.T., Khedher, N.B., Eldin, S.M., Fadhl, B.M., Khan, M.I.: Classification, Synthetic, and Characterization Approaches to Nanoparticles, and Their Applications in Various Fields of Nanotechnology: A Review. Catalysts. 12, 1386 (2022). https://doi.org/10.3390/catal12111386
33. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
34. Miao, L., Huang, L.: Exploring the Tumor Microenvironment with Nanoparticles. Cancer Treat Res. 166, 193–226 (2015). https://doi.org/10.1007/978-3-319-16555-4_9
35. Karimi, S., Bakhshali, R., Bolandi, S., Zahed, Z., Mojtaba Zadeh, S.S., Kaveh Zenjanab, M., Jahanban Esfahlan, R.: For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy. Materials Today Bio. 31, 101626 (2025). https://doi.org/10.1016/j.mtbio.2025.101626

36. Karimova, A.F., Khalitova, A.R., Suezov, R., Markov, N., Mukhamedshina, Y., Rizvanov, A.A., Huber, M., Simon, H.-U., Brichkina, A.: Immunometabolism of tumor-associated macrophages: A therapeutic perspective. European Journal of Cancer. 220, 115332 (2025). https://doi.org/10.1016/j.ejca.2025.115332
37. Yang, Y., Li, S., To, K.K.W., Zhu, S., Wang, F., Fu, L.: Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. Journal of Experimental & Clinical Cancer Research. 44, 145 (2025). https://doi.org/10.1186/s13046-025-03377-9
38. Glabman, R.A., Choyke, P.L., Sato, N.: Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy. Cancers (Basel). 14, 3906 (2022). https://doi.org/10.3390/cancers14163906
39. Ohue, Y., Nishikawa, H.: Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 110, 2080–2089 (2019). https://doi.org/10.1111/cas.14069
40. Zhang, A., Fan, T., Liu, Y., Yu, G., Li, C., Jiang, Z.: Regulatory T cells in immune checkpoint blockade antitumor therapy. Molecular Cancer. 23, 251 (2024). https://doi.org/10.1186/s12943-024-02156-y
41. Lu, J., Luo, Y., Rao, D., Wang, T., Lei, Z., Chen, X., Zhang, B., Li, Y., Liu, B., Xia, L., Huang, W.: Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol. 13, 39 (2024). https://doi.org/10.1186/s40164-024-00505-7
42. Kaminski, V. de L., Menezes, A.L.O., de Lima, K.G., de Almeida, S.L., da Silva, D.V.A., Franco, F.N., Preite, N.W., Loures, F.V.: Immunoregulation in Fungal Infections: A Review and Update on the Critical Role of Myeloid-Derived Suppressor Cells. Journal of Fungi. 11, 496 (2025). https://doi.org/10.3390/jof11070496
43. Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., Petrik, J.: Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers (Basel). 13, 4444 (2021). https://doi.org/10.3390/cancers13174444
44. Hu, Q., Zhu, Y., Mei, J., Liu, Y., Zhou, G.: Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 18, 65 (2025). https://doi.org/10.1186/s13045-025-01717-y
45. Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., Adam, V.: Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Journal of Hematology & Oncology. 15, 77 (2022). https://doi.org/10.1186/s13045-022-01292-6
46. Alum, E.U., Uti, D.E., Offor, C.E.: Redox Signaling Disruption and Antioxidants in Toxicology: From Precision Therapy to Potential Hazards. Cell Biochemistry and Biophysics. (2025). https://doi.org/10.1007/s12013-025-01846-8
47. Akwari, A.Ak., Okoroh, P.N., Aniokete, U.C., Abba, J.N., Uti, D.E.: Phytochemicals as modulators of ferroptosis: a novel therapeutic avenue in cancer and neurodegeneration. Mol Biol Rep. 52, 636 (2025). https://doi.org/10.1007/s11033-025-10752-4
48. Pérez-Tomás, R., Pérez-Guillén, I.: Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment. Cancers (Basel). 12, 3244 (2020). https://doi.org/10.3390/cancers12113244
49. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J Pers Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
50. Karnwal, A., Sharma, V., Kumar, G., Jassim, A.Y., Dohroo, A., Sivanesan, I.: Transforming Medicine with Nanobiotechnology: Nanocarriers and Their Biomedical Applications. Pharmaceutics. 16, 1114 (2024). https://doi.org/10.3390/pharmaceutics16091114
51. Din, F. ud, Aman, W., Ullah, I., Qureshi, O.S., Mustapha, O., Shafique, S., Zeb, A.: Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 12, 7291–7309 (2017). https://doi.org/10.2147/IJN.S146315
52. Majumder, J., Minko, T.: Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 18, 205–227 (2021). https://doi.org/10.1080/17425247.2021.1828339
53. Antonio, C.R., Trídico, L.A.: The importance of interaction between hyaluronic acid and CD44 receptor. S&CD. 13, (2021). https://doi.org/10.5935/scd1984-8773.2021130006
54. Gama, J.M., Oliveira, R.C.: CD44 and Its Role in Solid Cancers - A Review: From Tumor Progression to Prognosis and Targeted Therapy. Front Biosci (Landmark Ed). 30, 24821 (2025). https://doi.org/10.31083/FBL24821
55. Henke, E., Nandigama, R., Ergün, S.: Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 6, 160 (2020). https://doi.org/10.3389/fmolb.2019.00160
56. Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., Xiao, M.: Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Molecular Cancer. 22, 48 (2023). https://doi.org/10.1186/s12943-023-01744-8
57. Li, M., Zhang, Y., Zhang, Q., Li, J.: Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines. Mater Today Bio. 16, 100364 (2022). https://doi.org/10.1016/j.mtbio.2022.100364

58. Zatterale, F., Raciti, G.A., Prevenzano, I., Leone, A., Campitelli, M., De Rosa, V., Beguinot, F., Parrillo, L.: Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes. Biomolecules. 12, 982 (2022). https://doi.org/10.3390/biom12070982
59. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
60. Wright, K., Ly, T., Kriet, M., Czirok, A., Thomas, S.M.: Cancer-Associated Fibroblasts: Master Tumor Microenvironment Modifiers. Cancers (Basel). 15, 1899 (2023). https://doi.org/10.3390/cancers15061899
61. Mai, Z., Lin, Y., Lin, P., Zhao, X., Cui, L.: Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 15, 307 (2024). https://doi.org/10.1038/s41419-024-06697-4
62. Huang, Y., Fan, H., Ti, H.: Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy. Asian Journal of Pharmaceutical Sciences. 19, 100902 (2024). https://doi.org/10.1016/j.ajps.2024.100902
63. Wang, H., Li, J., Wang, Y., Gong, X., Xu, X., Wang, J., Li, Y., Sha, X., Zhang, Z.: Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy. Journal of Controlled Release. 319, 25–45 (2020). https://doi.org/10.1016/j.jconrel.2019.12.028
64. Chen, Y., Zhou, Q., Jia, Z., Cheng, N., Zhang, S., Chen, W., Wang, L.: Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression. Acta Pharm Sin B. 14, 3834–3854 (2024). https://doi.org/10.1016/j.apsb.2024.05.032
65. Lin, Y., Lin, P., Xu, R., Chen, X., Lu, Y., Zheng, J., Zheng, Y., Zhou, Z., Mai, Z., Zhao, X., Cui, L.: Nanovaccines empowering CD8+ T cells: a precision strategy to enhance cancer immunotherapy. Theranostics. 15, 3098–3121 (2025). https://doi.org/10.7150/thno.107856
66. Gurunathan, S., Thangaraj, P., Wang, L., Cao, Q., Kim, J.-H.: Nanovaccines: An effective therapeutic approach for cancer therapy. Biomedicine & Pharmacotherapy. 170, 115992 (2024). https://doi.org/10.1016/j.biopha.2023.115992

CITE AS: Nabuuma Ruth Nambi (2025). Tumor Microenvironment Modulation Using Nanotechnology: Reprogramming the Cancer Ecosystem. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):109-116. https://doi.org/10.59298/IDOSRJSR/2024/10.3.109116